Autopsy report · NCT01953874

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.

“SERVE-HF results showed ASV increased CV mortality in patients with reduced LVEF”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 2 years before it stopped.
126 participants enrolled.
Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status: Terminated
Phase: Na
Sponsor: ResMed
Sponsor type: Industry
Conditions: Acute Decompensated Heart Failure; Sleep Disordered Breathing
Interventions: MV ASV; Optimized Medical Treatment
Participants: 126
Sites: 15
Countries: Germany, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.